Fuqiang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fuqiang Wang has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Zhenyu Yin
Department of Hepatobiliary Surgery, Xiamen Key Laboratory of Liver Diseases, Xiamen Hospital of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Xiamen, China
9 shared publications Changhong Luo
Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, School of Medicine, Zhongshan Hospital of Xiamen University, Xiamen University, Xiamen, China
8 shared publications- Chengrong Xie
Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, School of Medicine, Zhongshan Hospital of Xiamen University, Xiamen University, Xiamen, China
8 shared publications Ping Zhan
Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, School of Medicine, Zhongshan Hospital of Xiamen University, Xiamen University, Xiamen, China
8 shared publicationsJing Lu
Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
6 shared publicationsQinliang Fang
Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, School of Medicine, Zhongshan Hospital of Xiamen University, Xiamen University, Xiamen, China
5 shared publications
Latest Publications
- Open Access
- 31 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Sophoricoside from sophora japonica L. is efficacious as monotherapy or in combination with lenvatinib in hepatocellular carcinoma via targeting EGFR
Sophora japonica L. is a commonly used traditional Chinese medicine. Sophoricoside (Sop), the isoflavone glycoside obtained in Sophora japonica L., is demonstrated with various pharmacological activities, such as anticancer, anti-inflammation, and immunosuppression. To data, there is a lack of comprehensive research examining the biological activity of Sop in hepatocellular carcinoma (HCC). The present work focused on investigating effects of Sop on treating HCC and exploring its underlying mechanisms. Here, we found that the treatment of Sop suppressed HCC cell proliferation and survival, arrested HCC cell cycle in vitro, and attenuated HCC growth in vivo. Additionally, Sop combined with lenvatinib elicited the synergy to resist HCC both in vitro and in vivo. Mechanistically, Sop could directly interact with epidermal growth factor receptor (EGFR) to induce its degradation. Such augmented antitumor impact of lenvatinib by Sop was achieved by suppressing the AKT and STAT3 signaling pathways. In conclusion, Sop serves as the strong EGFR inhibitor and the potential natural anti-tumor drug, which can be the sensitizer of lenvatinib for treating HCC via EGFR-AKT/STAT3 signaling, presenting auspicious implications for novel anti-HCC treatment strategies.
- 31 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessSophoricoside from sophora japonica L. is efficacious as monotherapy or in combination with lenvatinib in hepatocellular carcinoma via targeting EGFR
Sophora japonica L. is a commonly used traditional Chinese medicine. Sophoricoside (Sop), the isoflavone glycoside obtained in Sophora japonica L., is demonstrated with various pharmacological activities, such as anticancer, anti-inflammation, and immunosuppression. To data, there is a lack of comprehensive research examining the biological activity of Sop in hepatocellular carcinoma (HCC). The present work focused on investigating effects of Sop on treating HCC and exploring its underlying mechanisms. Here, we found that the treatment of Sop suppressed HCC cell proliferation and survival, arrested HCC cell cycle in vitro, and attenuated HCC growth in vivo. Additionally, Sop combined with lenvatinib elicited the synergy to resist HCC both in vitro and in vivo. Mechanistically, Sop could directly interact with epidermal growth factor receptor (EGFR) to induce its degradation. Such augmented antitumor impact of lenvatinib by Sop was achieved by suppressing the AKT and STAT3 signaling pathways. In conclusion, Sop serves as the strong EGFR inhibitor and the potential natural anti-tumor drug, which can be the sensitizer of lenvatinib for treating HCC via EGFR-AKT/STAT3 signaling, presenting auspicious implications for novel anti-HCC treatment strategies.
- Open Access
- 28 November 2025
- Published by Springer Nature in Oncogenesis
- Vol. 14 (1) , 46
Stabilization of FASN by USP5-mediated deubiquitination promotes hepatocellular carcinoma progression
The deubiquitinating enzyme Ubiquitin specific peptidase 5 (USP5) has attracted substantial notice for its vital role in cancer progression. However, the USP5-mediated deubiquitination of corresponding protein substrates and its functional role in hepatocellular carcinoma (HCC) have not been fully investigated. Here, we demonstrated that USP5 expression was significantly elevated in HCC tissues. The overexpression of USP5 was closely associated with larger tumor sizes, more satellite nodules and tumor emboli, and predicted unfavorable clinical outcome in HCC patients as well. Functionally, USP5 facilitated cell proliferation, migration, and invasion, and induced lipid accumulation in vitro, along with enhanced tumor growth in vivo. Moreover, knockdown of USP5 expression showed a profound effect on lipidomic profiling, specially reduced the content of palmitic acid (PA). Treatment of PA could partially rescue the suppression of HCC mediated by USP5 knockdown. Further mechanistic investigation uncovered that Fatty acid synthase (FASN), the crucial enzyme catalyzing PA synthesis, was a downstream target of USP5. USP5 interacted with FASN, repressing the ubiquitination modification of FASN and preventing its degradation. Notably, the positive correlation between USP5 and FASN expression in HCC tissues was observed, and USP5 exerted oncogenic effects partly via FASN. Our findings revealed that USP5 promotes HCC progression through deubiquitinating FASN, and targeting the USP5-FASN-PA axis could potentially serve as a strategic approach for the therapy of HCC.
- 28 November 2025
- Published by Springer Nature in Oncogenesis
- Vol. 14 (1) , 46
Open AccessStabilization of FASN by USP5-mediated deubiquitination promotes hepatocellular carcinoma progression
The deubiquitinating enzyme Ubiquitin specific peptidase 5 (USP5) has attracted substantial notice for its vital role in cancer progression. However, the USP5-mediated deubiquitination of corresponding protein substrates and its functional role in hepatocellular carcinoma (HCC) have not been fully investigated. Here, we demonstrated that USP5 expression was significantly elevated in HCC tissues. The overexpression of USP5 was closely associated with larger tumor sizes, more satellite nodules and tumor emboli, and predicted unfavorable clinical outcome in HCC patients as well. Functionally, USP5 facilitated cell proliferation, migration, and invasion, and induced lipid accumulation in vitro, along with enhanced tumor growth in vivo. Moreover, knockdown of USP5 expression showed a profound effect on lipidomic profiling, specially reduced the content of palmitic acid (PA). Treatment of PA could partially rescue the suppression of HCC mediated by USP5 knockdown. Further mechanistic investigation uncovered that Fatty acid synthase (FASN), the crucial enzyme catalyzing PA synthesis, was a downstream target of USP5. USP5 interacted with FASN, repressing the ubiquitination modification of FASN and preventing its degradation. Notably, the positive correlation between USP5 and FASN expression in HCC tissues was observed, and USP5 exerted oncogenic effects partly via FASN. Our findings revealed that USP5 promotes HCC progression through deubiquitinating FASN, and targeting the USP5-FASN-PA axis could potentially serve as a strategic approach for the therapy of HCC.
- Open Access
- 11 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1677724
Case Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy
Introduction: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with most patients diagnosed at advanced stages, often precluding surgical resection. Recently, immune checkpoint inhibitors, particularly PD-1 inhibitors, have emerged as promising therapies, though long-term disease-free survival (DFS) remains rare. We report a case of an advanced HCC patient who achieved complete remission (CR) after just four cycles of reduced-dose pembrolizumab and maintained a disease-free status for more than seven years. Case report: A 55-year-old male with chronic hepatitis B and alcohol-related liver disease presented with a ruptured HCC. After initial treatments, including surgery and chemotherapy, the patient was started on reduced-dose pembrolizumab (100 mg). After four cycles, the patient achieved CR. Conclusion: This case highlights the potential for long-term survival with reduced-dose PD-1 inhibitor therapy in advanced HCC. The patient’s exceptional response provides important insights into the role of personalized dosing, immune checkpoint inhibitors, and the management of immune-related adverse events.
- 11 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1677724
Open AccessCase Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy
Introduction: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with most patients diagnosed at advanced stages, often precluding surgical resection. Recently, immune checkpoint inhibitors, particularly PD-1 inhibitors, have emerged as promising therapies, though long-term disease-free survival (DFS) remains rare. We report a case of an advanced HCC patient who achieved complete remission (CR) after just four cycles of reduced-dose pembrolizumab and maintained a disease-free status for more than seven years. Case report: A 55-year-old male with chronic hepatitis B and alcohol-related liver disease presented with a ruptured HCC. After initial treatments, including surgery and chemotherapy, the patient was started on reduced-dose pembrolizumab (100 mg). After four cycles, the patient achieved CR. Conclusion: This case highlights the potential for long-term survival with reduced-dose PD-1 inhibitor therapy in advanced HCC. The patient’s exceptional response provides important insights into the role of personalized dosing, immune checkpoint inhibitors, and the management of immune-related adverse events.
- Open Access
- 10 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-18
METTL21A promotes hepatocellular carcinoma progression via methylating and stabilizing BAG3
Protein methyltransferases regulate diverse physiological and pathological processes through histone and non-histone substrate methylation. While the role of histone methyltransferases in tumorigenesis is well-established, the contribution of non-histone methyltransferases, particularly Methyltransferase 21A (METTL21A), to hepatocellular carcinoma (HCC) progression remains poorly characterized. Here, we report that METTL21A is significantly upregulated in HCC tissues and associated with poor clinical prognosis. Transcriptional activation by CCCTC-binding factor (CTCF) was identified as a key driver of METTL21A overexpression. Functional studies demonstrated that METTL21A promotes HCC growth and metastasis in both in vitro and in vivo models. Mechanistically, METTL21A mediates methylation of Bcl-2-associated athanogene-3 (BAG3), thereby inhibiting its ubiquitination and subsequent degradation. We further identified Tripartite motif containing 21 (TRIM21) as the E3 ligase responsible for BAG3 ubiquitination and found that METTL21A disrupts the TRIM21-BAG3 interaction. Notably, we discovered that the natural compound sophoricoside (Sop) acts as a METTL21A inhibitor and exhibits potent anti-HCC activity. Our study not only elucidates the oncogenic role and molecular mechanism of METTL21A in HCC progression but also highlights its therapeutic potential as a novel drug target for HCC treatment.
- 10 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-18
Open AccessMETTL21A promotes hepatocellular carcinoma progression via methylating and stabilizing BAG3
Protein methyltransferases regulate diverse physiological and pathological processes through histone and non-histone substrate methylation. While the role of histone methyltransferases in tumorigenesis is well-established, the contribution of non-histone methyltransferases, particularly Methyltransferase 21A (METTL21A), to hepatocellular carcinoma (HCC) progression remains poorly characterized. Here, we report that METTL21A is significantly upregulated in HCC tissues and associated with poor clinical prognosis. Transcriptional activation by CCCTC-binding factor (CTCF) was identified as a key driver of METTL21A overexpression. Functional studies demonstrated that METTL21A promotes HCC growth and metastasis in both in vitro and in vivo models. Mechanistically, METTL21A mediates methylation of Bcl-2-associated athanogene-3 (BAG3), thereby inhibiting its ubiquitination and subsequent degradation. We further identified Tripartite motif containing 21 (TRIM21) as the E3 ligase responsible for BAG3 ubiquitination and found that METTL21A disrupts the TRIM21-BAG3 interaction. Notably, we discovered that the natural compound sophoricoside (Sop) acts as a METTL21A inhibitor and exhibits potent anti-HCC activity. Our study not only elucidates the oncogenic role and molecular mechanism of METTL21A in HCC progression but also highlights its therapeutic potential as a novel drug target for HCC treatment.
- Open Access
- 27 February 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-16
PSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1
Hepatocellular carcinoma (HCC) is a highly potent malignancy. The enzyme coactivator-associated arginine methyltransferase 1 (CARM1) is highly expressed in different types of cancer. However, the precise levels of expression, clinical significance, biological functions, and molecular mechanisms of CARM1 in HCC, particularly related to the downstream genes regulated by CARM1 through histone arginine methylation, remain unclear. In this study, we presented findings from the TCGA database and clinical samples, which collectively demonstrated the overexpression of CARM1 in HCC. Additionally, we found that the upregulation of CARM1 was mediated by PSMD14-induced deubiquitination. CARM1 promoted the proliferation and metastasis of HCC cells in vitro and in vivo. Mechanistic investigations further revealed that FERMT1 is a downstream gene of CARM1, and CARM1 activates the transcription of FERMT1 through the dimethylation of arginine 17 on histone 3 (H3R17me2). Additionally, administering SGC2085, a CARM1 inhibitor, effectively suppressed the malignant behaviors of HCC cells. To summarize, our findings provided strong evidence that CARM1 can serve as a key oncoprotein; thus, it holds promise as a therapeutic target for HCC.
- 27 February 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-16
Open AccessPSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1
Hepatocellular carcinoma (HCC) is a highly potent malignancy. The enzyme coactivator-associated arginine methyltransferase 1 (CARM1) is highly expressed in different types of cancer. However, the precise levels of expression, clinical significance, biological functions, and molecular mechanisms of CARM1 in HCC, particularly related to the downstream genes regulated by CARM1 through histone arginine methylation, remain unclear. In this study, we presented findings from the TCGA database and clinical samples, which collectively demonstrated the overexpression of CARM1 in HCC. Additionally, we found that the upregulation of CARM1 was mediated by PSMD14-induced deubiquitination. CARM1 promoted the proliferation and metastasis of HCC cells in vitro and in vivo. Mechanistic investigations further revealed that FERMT1 is a downstream gene of CARM1, and CARM1 activates the transcription of FERMT1 through the dimethylation of arginine 17 on histone 3 (H3R17me2). Additionally, administering SGC2085, a CARM1 inhibitor, effectively suppressed the malignant behaviors of HCC cells. To summarize, our findings provided strong evidence that CARM1 can serve as a key oncoprotein; thus, it holds promise as a therapeutic target for HCC.
- Open Access
- 17 October 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-15
TRIM55 restricts the progression of hepatocellular carcinoma through ubiquitin-proteasome-mediated degradation of NF90
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor worldwide. Tripartite motif containing 55 (TRIM55), also known as muscle-specific ring finger 2 (Murf2), belongs to the TRIM protein family and serves as an E3 ligase. Recently, the function and mechanism of TRIM55 in the advancement of solid tumors have been elucidated. However, the role of TRIM55 and its corresponding protein substrates in HCC remains incompletely explored. In this study, we observed a significant reduction in TRIM55 expression in HCC tissues. The downregulation of TRIM55 expression correlated with larger tumor size and elevated serum alpha-fetoprotein (AFP), and predicted unfavorable overall and tumor-free survival. Functional experiments demonstrated that TRIM55 suppressed the proliferation, migration, and invasion of HCC cells in vitro, as well as hindered HCC growth and metastasis in vivo. Additionally, TRIM55 exhibited a suppressive effect on HCC angiogenesis. Mechanistically, TRIM55 interacted with nuclear factor 90 (NF90), a double-stranded RNA-binding protein responsible for regulating mRNA stability and gene transcription, thereby facilitating its degradation via the ubiquitin-proteasome pathway. Furthermore, TRIM55 attenuated the association between NF90 and the mRNA of HIF1α and TGF-β2, consequently reducing their stability and inactivating the HIF1α/VEGF and TGFβ/Smad signaling pathways. In conclusion, our findings unveil the important roles of TRIM55 in suppressing the progression of HCC partly by promoting the degradation of NF90 and subsequently modulating its downstream pathways, including HIF1α/VEGF and TGFβ/Smad signaling.
- 17 October 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-15
Open AccessTRIM55 restricts the progression of hepatocellular carcinoma through ubiquitin-proteasome-mediated degradation of NF90
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor worldwide. Tripartite motif containing 55 (TRIM55), also known as muscle-specific ring finger 2 (Murf2), belongs to the TRIM protein family and serves as an E3 ligase. Recently, the function and mechanism of TRIM55 in the advancement of solid tumors have been elucidated. However, the role of TRIM55 and its corresponding protein substrates in HCC remains incompletely explored. In this study, we observed a significant reduction in TRIM55 expression in HCC tissues. The downregulation of TRIM55 expression correlated with larger tumor size and elevated serum alpha-fetoprotein (AFP), and predicted unfavorable overall and tumor-free survival. Functional experiments demonstrated that TRIM55 suppressed the proliferation, migration, and invasion of HCC cells in vitro, as well as hindered HCC growth and metastasis in vivo. Additionally, TRIM55 exhibited a suppressive effect on HCC angiogenesis. Mechanistically, TRIM55 interacted with nuclear factor 90 (NF90), a double-stranded RNA-binding protein responsible for regulating mRNA stability and gene transcription, thereby facilitating its degradation via the ubiquitin-proteasome pathway. Furthermore, TRIM55 attenuated the association between NF90 and the mRNA of HIF1α and TGF-β2, consequently reducing their stability and inactivating the HIF1α/VEGF and TGFβ/Smad signaling pathways. In conclusion, our findings unveil the important roles of TRIM55 in suppressing the progression of HCC partly by promoting the degradation of NF90 and subsequently modulating its downstream pathways, including HIF1α/VEGF and TGFβ/Smad signaling.
- Open Access
- 1 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma
UBE2C, a ubiquitin-conjugating enzyme, functions as an oncogene in different types of human cancers. Nonetheless, the exact influence of UBE2C on the development of HCC via regulation of ubiquitination remains uncertain. Here, we found that UBE2C displayed elevated levels of expression in HCC and was associated with an unfavorable prognosis, as evidenced by the analysis of the TCGA database and the examination of clinical specimens. The role of UBE2C in HCC revealed its ability to promote the growth and metastasis of HCC. Mechanistically, UBE2C activated Notch signaling, as evidenced by the upregulation of N1ICD and Hes1, crucial components of the Notch pathway, and activation of the RBP-JK luciferase reporter by UBE2C. Finally, rescue experiments demonstrated that the oncogenic role of UBE2C was eliminated through treatment with the Notch inhibitor DAPT, while overexpression of N1ICD alleviated the anticarcinogenic impact of knockdown of UBE2C. Altogether, the results of our study indicate that UBE2C plays a role in the activation of Notch signaling and could potentially serve as a viable target for therapeutic interventions in HCC.
- 1 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Open AccessThe activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma
UBE2C, a ubiquitin-conjugating enzyme, functions as an oncogene in different types of human cancers. Nonetheless, the exact influence of UBE2C on the development of HCC via regulation of ubiquitination remains uncertain. Here, we found that UBE2C displayed elevated levels of expression in HCC and was associated with an unfavorable prognosis, as evidenced by the analysis of the TCGA database and the examination of clinical specimens. The role of UBE2C in HCC revealed its ability to promote the growth and metastasis of HCC. Mechanistically, UBE2C activated Notch signaling, as evidenced by the upregulation of N1ICD and Hes1, crucial components of the Notch pathway, and activation of the RBP-JK luciferase reporter by UBE2C. Finally, rescue experiments demonstrated that the oncogenic role of UBE2C was eliminated through treatment with the Notch inhibitor DAPT, while overexpression of N1ICD alleviated the anticarcinogenic impact of knockdown of UBE2C. Altogether, the results of our study indicate that UBE2C plays a role in the activation of Notch signaling and could potentially serve as a viable target for therapeutic interventions in HCC.
- Open Access
- 18 January 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (2) , 1712-1732
Malignant cell receptor-ligand subtypes guide the prediction of prognosis and personalized immunotherapy of liver cancer
Objective: Liver cancer is a prevalent disease with a dismal prognosis. The aim of the research is to identify subgroups based on malignant cell receptor ligand gene from single-cell RNA, which might lead to customized immunotherapy for patients with liver cancer. Methods: Based on scRNA-seq data, we identified the receptor-ligand genes associated with prognosis and classify patients into molecular subtypes by univariate Cox regression and consensus clustering. LASSO regression was performed to construct a prognostic model, which was validated in TCGA and ICGC datasets. Immune infiltration and prediction of immunotherapy response were analyzed using ssGSEA, ESTIMATE, TIDE, and TRS score calculation. Finally, qPCR and Western blot validation of key genes and protein levels in cell lines. Results: A risk model using 16-gene expression levels predicted liver cancer patients’ prognosis. The RiskScore associated significantly with tumor clinical characteristics and immunity, integrated with clinicopathological features for survival prediction. Differential expression of SRXN1 was verified in hepatocellular carcinoma and normal liver cells. Conclusion: Our study utilizes single-cell analysis to investigate the communication between malignant cells and other cell types, identifying molecular subtypes based on malignant cell receptor ligand genes, offering new insights for the development of personalized immunotherapy and prognostic prediction models.
- 18 January 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (2) , 1712-1732
Open AccessMalignant cell receptor-ligand subtypes guide the prediction of prognosis and personalized immunotherapy of liver cancer
Objective: Liver cancer is a prevalent disease with a dismal prognosis. The aim of the research is to identify subgroups based on malignant cell receptor ligand gene from single-cell RNA, which might lead to customized immunotherapy for patients with liver cancer. Methods: Based on scRNA-seq data, we identified the receptor-ligand genes associated with prognosis and classify patients into molecular subtypes by univariate Cox regression and consensus clustering. LASSO regression was performed to construct a prognostic model, which was validated in TCGA and ICGC datasets. Immune infiltration and prediction of immunotherapy response were analyzed using ssGSEA, ESTIMATE, TIDE, and TRS score calculation. Finally, qPCR and Western blot validation of key genes and protein levels in cell lines. Results: A risk model using 16-gene expression levels predicted liver cancer patients’ prognosis. The RiskScore associated significantly with tumor clinical characteristics and immunity, integrated with clinicopathological features for survival prediction. Differential expression of SRXN1 was verified in hepatocellular carcinoma and normal liver cells. Conclusion: Our study utilizes single-cell analysis to investigate the communication between malignant cells and other cell types, identifying molecular subtypes based on malignant cell receptor ligand genes, offering new insights for the development of personalized immunotherapy and prognostic prediction models.
- Open Access
- 8 December 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-10
Heat shock protein HSPA13 promotes hepatocellular carcinoma progression by stabilizing TANK
HSPA13, an important member of the heat shock protein family, plays an essential role in the oncogenesis of many organs, but the mechanism and function in hepatocellular carcinoma (HCC) is still unclear. In the present study, we found that HSPA13 was highly expressed in HCC and predicted poor clinical prognosis. Upregulation of HSPA13 was significantly associated with vascular invasion in HCC patients. Functionally, knockdown experiments demonstrated that HSPA13 promoted HCC proliferation, migration, and invasion. Mechanistic investigation showed that HSPA13 could interact with TANK to inhibit its ubiquitination and degradation. In addition, the expression of HSPA13 and TANK were positively correlated in HCC tissues. To conclude, the present study uncovers the oncogenic function of HSPA13 in the progression of HCC by regulating the stability of TANK. These findings suggest that HSPA13 and TANK may serve as promising targets for the diagnosis and treatment of HCC.
- 8 December 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-10
Open AccessHeat shock protein HSPA13 promotes hepatocellular carcinoma progression by stabilizing TANK
HSPA13, an important member of the heat shock protein family, plays an essential role in the oncogenesis of many organs, but the mechanism and function in hepatocellular carcinoma (HCC) is still unclear. In the present study, we found that HSPA13 was highly expressed in HCC and predicted poor clinical prognosis. Upregulation of HSPA13 was significantly associated with vascular invasion in HCC patients. Functionally, knockdown experiments demonstrated that HSPA13 promoted HCC proliferation, migration, and invasion. Mechanistic investigation showed that HSPA13 could interact with TANK to inhibit its ubiquitination and degradation. In addition, the expression of HSPA13 and TANK were positively correlated in HCC tissues. To conclude, the present study uncovers the oncogenic function of HSPA13 in the progression of HCC by regulating the stability of TANK. These findings suggest that HSPA13 and TANK may serve as promising targets for the diagnosis and treatment of HCC.
- 25 May 2023
- Published by Springer Nature in Human Cell
- Vol. 36 (4) , 1477-1484
Upregulation of helicase-like transcription factor predicts poor prognosis and facilitates hepatocellular carcinoma progression
Helicase-like transcription factor (HLTF) belongs to the family of SWI/SNF proteins, which has been reported to exert oncogenic function in several human cancers. However, to date, its functional role in hepatocellular carcinoma (HCC) has not been revealed. Here, we found that HLTF was highly expressed in HCC tissues compared to nontumor tissues. Additionally, upregulation of HLTF was significantly associated with poor prognosis of patients with HCC. Functional experiments demonstrated that knockdown of HLTF expression significantly inhibited the proliferation, migration, and invasion of HCC cells in vitro, and suppressed tumor growth in vivo. In conclusion, our results suggest that upregulation of HLTF is associated with the development of HCC, and HLTF may be a potential therapeutic target for HCC treatment.
- 25 May 2023
- Published by Springer Nature in Human Cell
- Vol. 36 (4) , 1477-1484
Upregulation of helicase-like transcription factor predicts poor prognosis and facilitates hepatocellular carcinoma progression
Helicase-like transcription factor (HLTF) belongs to the family of SWI/SNF proteins, which has been reported to exert oncogenic function in several human cancers. However, to date, its functional role in hepatocellular carcinoma (HCC) has not been revealed. Here, we found that HLTF was highly expressed in HCC tissues compared to nontumor tissues. Additionally, upregulation of HLTF was significantly associated with poor prognosis of patients with HCC. Functional experiments demonstrated that knockdown of HLTF expression significantly inhibited the proliferation, migration, and invasion of HCC cells in vitro, and suppressed tumor growth in vivo. In conclusion, our results suggest that upregulation of HLTF is associated with the development of HCC, and HLTF may be a potential therapeutic target for HCC treatment.